When Maryam Hassan began experiencing headaches so severe they vanished only when she lay flat, doctors struggled for answers—until now. Her journey mirrors that of countless others with spontaneous cerebrospinal fluid (CSF) leaks, a condition so debilitating it can confine people to bed for months. Now, researchers at Cedars-Sinai and Johns Hopkins University have uncovered a genetic clue that could transform how medicine understands and treats these mysterious leaks. For the first time, mutations in the FBN2 gene have been linked to unexplained spinal CSF leaks, offering hope to patients long dismissed as medical mysteries.
Spinal CSF leaks occur when the membrane surrounding the spinal cord tears, allowing cerebrospinal fluid to escape. This leads to excruciating headaches, neck stiffness, and nausea—symptoms that worsen upright and improve when lying down. While treatments like epidural blood patches or surgery can patch the leak, they don’t address the root cause. And for many patients, no underlying condition is ever found. But subtle signs of connective tissue weakness have long hinted at a deeper genetic origin.
To uncover it, Dr. Cassie Parks, lead author of the study, and co-senior authors Dr. Wouter Schievink and Dr. Hal Dietz analyzed whole-exome sequencing data from 42 patients with unexplained spinal CSF leaks. They compared this group to more than 3,800 individuals without the condition. The results, published in The Lancet Neurology, revealed that approximately 1 in 5 patients with spontaneous CSF leaks carried rare variants in the FBN2 gene—variants nearly absent in the control group. These mutations affect fibrillin-2, a protein critical for connective tissue strength, particularly in the dura mater, the tough membrane encasing the spinal cord.
In follow-up experiments, the team showed that these genetic changes impair how cells adhere to the extracellular matrix, weakening structural support around the spine. Even more compelling, laboratory mice engineered with the same FBN2 mutations developed fragile spinal linings prone to tearing—mimicking the human condition. This functional evidence confirms that FBN2 defects aren’t just correlated with CSF leaks; they likely play a causal role.
The discovery opens new doors for prevention and treatment. Instead of reacting to leaks after they happen, clinicians may one day intervene earlier—using medications that stabilize connective tissue or correct the biological pathways disrupted by FBN2. "By identifying a genetic contributor, we now have the first understanding of cellular events that may be targetable for prevention or treatment of spontaneous CSF leaks," said Dr. Dietz. For patients like Maryam, whose life was upended by a condition few understood, this breakthrough isn’t just scientific progress—it’s a promise of dignity, mobility, and relief. As research moves toward targeted therapies, the horizon for those living with invisible, painful disorders grows suddenly brighter.